Page 4 - தலைமை இயங்குகிறது அதிகாரி கேன் கோவன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தலைமை இயங்குகிறது அதிகாரி கேன் கோவன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தலைமை இயங்குகிறது அதிகாரி கேன் கோவன் Today - Breaking & Trending Today

BioVaxys Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program

Features Observation Of Neutralizing Antibodies To SARS-CoV-2
Advancement Of Viral Vaccine Platform And T-cell Diagnostic To Address Emerging SARS-CoV-2 Strains
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF)
( BioVaxys or Company ) is pleased to provide a corporate update on recent advancements of its vaccine platforms, and viral diagnostic and corporate objectives for 2021. BioVaxys is pleased to announce that it has commenced the clinical development program for BVX-0918A, its haptenized tumor antigen vaccine for ovarian cancer. The Company plans to seek a compassionate use approval in the European Union ( EU ) for Stage III & Stage IV ovarian cancer, followed by submitting an IND in the US. BioVaxys is in discussions with its designated Contract Manufacturing Organization ( CMO ) and anticipates the execution of a manufacturing contract in 1Q21. The Company plans to submit its Clinical Trial Application ( CTA ) for BVX-0918A with the European Med ....

United States , South Africa , United Kingdom , British Columbia , South African , Biovaxy Covid , Nikita Sashdev , Ken Kovan , Contract Development , Wexner School Of Medicine , Contract Manufacturing Organization , Us Department Of Health , Ohio State University , Human Services , Drug Administration , Manufacturing Organization , Charles River Laboratories Inc , Biovaxys Technology Corp , European Union , European Medicines Agency , Biovaxys Or Company , American Cancer Society , Vaxys Technology , Clinical Trial Application , Chief Medical Officer , David Berd ,

Financial News Media | BioVaxys Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program and Vaccine Platform Expansion

Vancouver, BC – January 25, 2021 –
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) (“BioVaxys” or “Company”) is pleased to provide a corporate update on recent advancements of its vaccine platforms, viral diagnostic and corporate objectives for 2021. BioVaxys is pleased to announce that it has commenced the clinical development program for BVX-0918A, its haptenized tumor antigen vaccine for ovarian cancer. The Company plans to seek a compassionate use approval in the European Union (“EU”) for Stage III & Stage IV ovarian cancer, followed by submitting an IND in the US. BioVaxys is in discussions with its designated Contract Manufacturing Organization (“CMO”) and anticipates the execution of a manufacturing contract in 1Q21. The Company plans to submit its Clinical Trial Application (“CTA”) for BVX-0918A with the European Medicines Agency (“EMEA”) later this year. ....

United States , South Africa , United Kingdom , British Columbia , South African , Biovaxy Covid , Nikita Sashdev , Ken Kovan , Contract Development , Contract Manufacturing Organization , Ohio State University , Preclinical Program , Manufacturing Organization , Biovaxys Technology Corp , European Union , Biovaxys Or Company , American Cancer Society , Wexner School Of Medicine , Human Services , Us Department Of Health , Drug Administration , Charles River Laboratories Inc , European Medicines Agency , Biovaxys Announces Initiation , Cancer Vaccine , Vaccine Platform Expansion ,